Erebagen
Erebagen is a synthetic biology company that discovers truly novel bioactive products from microbes by activating previously silent gene clusters
There is a lot still to be discovered in microbial genomes and Erebagen is using its platform technology to discover new:
- Compounds The structurally diverse bioactive compounds produced by microbes that can act as fantiastic starting points in developing new drugs
- Chemistry How the biocatalysts involved on the production of metabolites work and how they can be used to perform unnatural reactions
- Control How biosynthetic pathways in microbes are controlled by regulators and how we can use these regulators to activate silent parts of the genomes
We are preparing a future round of fund raising and if you would like to hear about our eningeering platform, our buisness plan or how you could work with us please reach out to us
Isogenica
Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.
Sphere Fluidics
Sphere Fluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.
Specialities
Biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells
